ADC Therapeutics to Attend 2024 RBC Healthcare Conference

LAUSANNE, Switzerland, May 09, 2024 – ADC Therapeutics SA (NYSE: ADCT) has announced that Chief Executive Officer Ameet Mallik will be participating in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference. This event is scheduled for Tuesday, May 14, 2024, at 1:35 p.m. ET. The presentation will be accessible through a live webcast on the Events & Presentations page in the Investors section of ADC Therapeutics' website. The webcast will be available for replay for about 30 days following the event.

ADC Therapeutics is a global, commercial-stage leader in the field of antibody drug conjugates (ADCs). The company is working on advancing its proprietary ADC technology with the goal of changing the treatment landscape for patients suffering from hematologic malignancies and solid tumors. 

Their CD19-targeting ADC, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma, specifically for patients who have undergone at least two prior lines of systemic therapy. ZYNLONTA is also undergoing development in combination with other agents and for use in earlier lines of treatment. Beyond ZYNLONTA, ADC Therapeutics has multiple ADCs in various stages of clinical and preclinical development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!